Exact Sciences Q4 EPS Estimate Decreased by Leerink Partnrs

Exact Sciences Co. (NASDAQ:EXAS) – Equities research analysts at Leerink Partnrs lowered their Q4 2024 earnings estimates for shares of Exact Sciences in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn ($0.31) per share for the quarter, down from their previous forecast of ($0.30). The consensus estimate for Exact Sciences’ current full-year earnings is ($1.10) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q2 2025 earnings at $0.02 EPS.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. The business’s revenue was up 12.8% on a year-over-year basis.

Several other research analysts also recently weighed in on EXAS. Citigroup reduced their price target on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Canaccord Genuity Group dropped their price objective on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Sanford C. Bernstein upped their price objective on shares of Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Bank of America dropped their price objective on shares of Exact Sciences from $75.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Finally, Piper Sandler dropped their price objective on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Stock Up 1.5 %

EXAS opened at $55.98 on Thursday. Exact Sciences has a twelve month low of $40.62 and a twelve month high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The company has a 50-day moving average price of $57.54 and a 200 day moving average price of $59.40. The company has a market cap of $10.36 billion, a PE ratio of -47.85 and a beta of 1.24.

Hedge Funds Weigh In On Exact Sciences

Large investors have recently made changes to their positions in the stock. WCM Investment Management LLC lifted its holdings in Exact Sciences by 1,153.2% during the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock worth $12,388,000 after buying an additional 172,821 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in Exact Sciences by 67.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock worth $1,994,000 after buying an additional 11,800 shares in the last quarter. Zacks Investment Management acquired a new stake in Exact Sciences during the 3rd quarter worth approximately $2,083,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Exact Sciences by 59.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock worth $22,868,000 after buying an additional 125,192 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Exact Sciences by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock worth $88,017,000 after buying an additional 45,015 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Exact Sciences

In related news, CEO Kevin T. Conroy acquired 19,500 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were purchased at an average cost of $51.35 per share, for a total transaction of $1,001,325.00. Following the acquisition, the chief executive officer now owns 1,074,191 shares in the company, valued at $55,159,707.85. The trade was a 1.85 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.36% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.